Blackford, IBM team up on automated image registration
IBM Watson Health will integrate an automatic image registration application...Read more on AuntMinnie.comRelated Reading: Guerbet, IBM partner on AI for prostate cancer IBM launches Imaging Patient Synopsis IBM inks AI deals with Vanderbilt, Brigham and Women's Densitas inks partner agreement with Blackford Intelerad unveils AI initiative, expands Blackford deal Blackford to launch Smart Localizer at SIIM
Authors: Yan M, Zhao T, Fu L, Tian R, Li D, Da Y Abstract Long non-coding RNA (lncRNA) prostate cancer-associated transcript 1 (PCAT-1) is a long non-coding RNA involved in the development of various cancer types. Tongue squamous cell carcinoma (TSCC) is the most frequently diagnosed type of oral cancer worldwide. The present study aimed to explore the role of lncRNA PCAT-1 in TSCC, and to provide a preliminary assessment of the downstream pathways involved. The expression levels of lncRNA PCAT-1 in TSCC specimens were first assessed. Subsequently, lncRNA PCAT-1 was knocked down in TSCC cell lines and the resulting...
Transgender children and adolescents may present to care for puberty suppression to prevent undesired and potentially irreversible phenotypic changes that are incongruent with their gender identity. Though histrelin implants have been approved and studied for hormonal axis suppression in medical conditions such as prostate cancer and central precocious puberty, limited data describe its use among children and adolescents with gender dysphoria. Our study aims to characterize the use of the histrelin implant for puberty suppression among transgender youth.
ConclusionPre-clinical experiments demonstrated promising results for in-situ confirmation of lesion locations in prostates using Raman spectroscopy, both in phantoms and human ex-vivo prostate tissue, which is required for integration in HDR brachytherapy procedures.
Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Publication date: Available online 27 March 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Haisong Tan, Nan Hou, Yanlei Liu, Bin Liu, Wen Cao, Dachao Zheng, Wenzhi Li, Yushan Liu, Bin Xu, Zhong Wang, Daxiang Cui
AbstractMultiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
Conclusions: The recently developed MRI ADC map-based radiomics model was validated in terms of its predictive accuracy of BCR and bRFS after prostatectomy in an external cohort.
Publication date: Available online 27 March 2020Source: Academic RadiologyAuthor(s): Harrison Kim, John V. Thomas, Jeffrey W. Nix, Jennifer B. Gordetsky, Yufeng Li, Soroush Rais-Bahrami
Stereotactic ablative radiotherapy (SABR) of oligometastatic disease was superior to observation in men with hormone-sensitive prostate cancer.Medscape Medical News
Conclusion: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.